Search research articles
Contact Us
Filters
Showing results (61-70 of 85) with videos related to
Page
of 9
Sort By:
Breast Cancer Research and Treatment
|
August 10, 2007
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer
Valentina Guarneri, Antonio Frassoldati, Guido Ficarra, et al.
Diagnostics (Basel, Switzerland)
|
January 22, 2021
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Matteo Santoni, Francesco Massari, Sergio Bracarda, et al.
Targeted Oncology
|
November 10, 2020
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study
Luca Faloppi, Marco Puzzoni, Andrea Casadei Gardini, et al.
Targeted Oncology
|
February 6, 2020
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study
Luca Faloppi, Marco Puzzoni, Andrea Casadei Gardini, et al.
Targeted Oncology
|
August 2, 2021
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
Matteo Santoni, Francesco Massari, Enrique Grande, et al.
Targeted Oncology
|
August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies
Matteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Human Mutation
|
March 11, 2026
Oncological Genetic Counseling in Hereditary Breast and Ovarian Cancers and Lynch Syndrome High-Risk Subjects: Evaluation of Efficacy and Outcomes Using the Genomics Outcome Scale
Elena Maccaroni, Rebecca Chiariotti, Riccardo Giampieri, et al.
Clinical & Experimental Metastasis
|
November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study
Renate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 85) with videos related to
Sort By:
Page
of 9
Breast Cancer Research and Treatment
|
August 10, 2007
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer
Valentina Guarneri, Antonio Frassoldati, Guido Ficarra, et al.
Diagnostics (Basel, Switzerland)
|
January 22, 2021
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Matteo Santoni, Francesco Massari, Sergio Bracarda, et al.
Targeted Oncology
|
November 10, 2020
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study
Luca Faloppi, Marco Puzzoni, Andrea Casadei Gardini, et al.
Targeted Oncology
|
February 6, 2020
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study
Luca Faloppi, Marco Puzzoni, Andrea Casadei Gardini, et al.
Targeted Oncology
|
August 2, 2021
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
Matteo Santoni, Francesco Massari, Enrique Grande, et al.
Targeted Oncology
|
August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies
Matteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Human Mutation
|
March 11, 2026
Oncological Genetic Counseling in Hereditary Breast and Ovarian Cancers and Lynch Syndrome High-Risk Subjects: Evaluation of Efficacy and Outcomes Using the Genomics Outcome Scale
Elena Maccaroni, Rebecca Chiariotti, Riccardo Giampieri, et al.
Clinical & Experimental Metastasis
|
November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study
Renate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Page
of 9